Similarly, the blockade of the CD6-CD318 interaction by itolizumab increases the cytotoxicity of CD8+ T and NK cells over CD318+ tumor lines, reverses the NKG2A/NKG2D ratio, and increases granzyme B and IFNγ production. The gene discussed is CD6; the disease is neoplasm.